



P: +612 9889 5171
F: +612 9888 6276
E: general@cfa.org.au
Rose Cottage
2 Richardson Place
North Ryde NSW 2113
(PO Box 268)
North Ryde NSW 1670

ACN 104 285 136 (DGR
Endorsed)

Professor Andreas Fouras
Australian Lung Health Initiative Pty Ltd
169 Fullarton Road
Dulwich SA 5065

22 February 2019

Dear Professor

As you will know, cystic fibrosis (CF) is the most common life threatening inherited condition that Australians face. CF affects many part of the body, particularly the lungs where thick, sticky mucus build up results in repeated lung infections. That steadily worsen over time and result in early death.

Cystic Fibrosis Australia (CFA) is the national CF organisation responsible for advocacy on behalf of the CF community, promoting CF research in order to enhance the well-being of the CF community and raising awareness about CF. CFA is always looking for ways to improve the longevity of people with CF and ensure they have the best quality of life.

CFA is aware of the Frontiers project "*4D Functional Diagnosis: A New Frontier in Lung Health for Children*" being submitted by the ALHI, to seek funding to develop what we see as truly next-generation lung health assessment capabilities, starting with creation of a paediatric scanner to let doctors find and measure the level of lung disease in children under 6 years of age.

This is a highly worthy goal, as one of the major problems in fighting CF is that there are no lung function tests that can be used in children like these, and that means doctors cannot get enough information to be able to provide effective and safe treatment.

CFA understands that this XV technology now requires significant investment to reach this goal, and CFA fully and enthusiastically supports the project and we will offer any assistance we can as the project proceeds through animal studies to clinical trials of the XV scanners.

We expect that using this lung function assessment technology in people born with CF will result in far earlier diagnosis of lung infections, and the ability to actually prevent CF disease establishing, or progressing, making a huge difference to the lives of our CF members, their families and friends, and greatly reduce the costs of living with CF for both our members and for the health system.

CFA looks forward to the development and commercialisation of XV imaging to the benefit of people with CF. In summary, CFA strongly supports the efforts 4Dx is making to obtain funding via the Frontiers grant scheme to bring this unique lung diagnostic technology to Australia and the world.

Kind regards

A handwritten signature in black ink, appearing to read "Nettie Burke".

Nettie Burke, CEO (0404 034 294)
Cystic Fibrosis Australia